Chris P. Recknor - Mar 31, 2022 Form 4 Insider Report for CytoDyn Inc. (CYDY)

Role
Officer
Signature
/s/ Antonio Migliarese, Attorney-In-Fact
Stock symbol
CYDY
Transactions as of
Mar 31, 2022
Transactions value $
$0
Form type
4
Date filed
6/8/2022, 04:06 PM
Previous filing
Aug 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYDY Common Stock Award $0 +13K +1.89% $0.00 699K Mar 31, 2022 Direct F1
transaction CYDY Common Stock Award $0 +17.7K +2.54% $0.00 717K Apr 15, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Chris P. Recknor is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.

Remarks:

Sr. VP Clinical Operations, Dr Chris P. Recknor served in the position of Sr. VP Clinical Operations until 4/19/2022. EX 24 - Power of Attorney